12/08/2017 12:05:19

IGE+XAO: Declaration of the own share transactions (as of 10 August 2017) made within the share buy-back program approved by the Combined General Meeting of 27 January 2017

IGE+XAO

Société Anonyme au capital de 5 497 030 euros

Siège social : 16 Boulevard Déodat de Séverac

31770 COLOMIERS

338 514 987 RCS Toulouse

Regulated information

Declaration of the own share transactions (as of 10 August 2017) made within the share buy-back program approved by the Combined General Meeting of 27 January 2017

Detailed information is available on

http://www.ige-xao.com/en/company/investors/regulated-information/holding-of-share-capital/declaration-about-monthly-share-purchases/declaration-of-the-own-share-transactions-made-within-the-share-buy-back-program-as-of-10-august-2017

Name of the issuer

Issuer identification code

Day of the transaction

Identification code of the financial instrument

Daily total volume (in number of shares)

Daily weighted average price

Market

IGE XAO 969500PQ2JNC0EOG2K85 24/02/2017 FR0000030827 191 84.00 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 27/02/2017 FR0000030827 191 83.4602 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 31/03/2017 FR0000030827 102 87.88 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 03/04/2017 FR0000030827 106 87.04 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 28/06/2017 FR0000030827 10,526 95.00 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 20/07/2017 FR0000030827 87 98.50 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 27/07/2017 FR0000030827 10,100 99.00 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 28/07/2017 FR0000030827 83 98.50 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 03/08/2017 FR0000030827 174 98.8481 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 04/08/2017 FR0000030827 176 98.85 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 07/08/2017 FR0000030827 195 97.49 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 09/08/2017 FR0000030827 200 97.00 XPAR (Euronext - Euronext Paris)
IGE XAO 969500PQ2JNC0EOG2K85 10/08/2017 FR0000030827 85 97.00 XPAR (Euronext - Euronext Paris)

ABOUT THE IGE+XAO GROUP

For over 31 years, the IGE+XAO Group has been a software publisher designing, producing, selling and supporting a range of Computer Aided Design (CAD), Product Lifecycle Management (PLM) and Simulation software dedicated to Electrical Engineering. These software products have been designed to help manufacturers in the design and maintenance of the electrical part of any type of installation. This type of CAD/PLM/Simulation is called "Electrical CAD/PLM/Simulation". IGE+XAO has built a range of Electrical CAD/PLM/Simulation software designed for all the manufacturers. IGE+XAO employs 390 people around the world at 33 sites and in 22 countries, and has more than 86,400 licences distributed around the world. IGE+XAO is a reference in its field. For more information: http://www.ige-xao.com.

IGE+XAO GROUP CONTACTS

IGE+XAO Group, 16 Boulevard Déodat de Séverac - CS 90312 - 31773 Colomiers cedex - France

Phone: +33 (0)5 62 74 36 36 - Fax: +33 (0)5 62 74 36 37 - www.ige-xao.com

Listed on NYSE Euronext Paris - Compartment C - ISIN FR 0000030827

EnterNext© PEA-PME 150 index

Analysts/ Investors contact: Alain Di Crescenzo (Chairman of the Group): +33 (0)5 62 74 36 36

Press contact: Rozenn Nerrand-Destouches +33 (0)5 62 74 36 02

IGE+XAO: Declaration of the own share transactions


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: IGE+XAO via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Oct
VWS
Der er for tiden en del debat omkring øget prispres på vindmøllemarkedet - bl.a. som følge af at Sie..
78
20 Oct
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker min analyse af Pandoras forretningsm..
59
18 Oct
EI
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
43
18 Oct
NOVO-B
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
21
20 Oct
TEVA
Jeg deler spekulationerne omkring Kåres tiltrædelse dvs. den dårlige nyhedsstrøm er snart slut. Min ..
19
18 Oct
EI
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
17
18 Oct
PNDORA
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
14
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
14
20 Oct
PNDORA
lugte af noget personligt mod alfinvest, vil jeg nu tillade mig at drage tvivl, både ved hans hensig..
13
20 Oct
PNDORA
Vanvittigt godt formuleret Peter. Det er næsten som at tage på universitetet og studere grønlandsk a..
13

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
2
Sequent Announces Two New Sequent Platform Versions
3
Simmons Reports Third Quarter 2017 Earnings
4
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
5
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 18:09:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:09:06 - 2017-10-23 18:09:06 - 1000 - Website: OKAY